API Intermediate Market By Type, By Application, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

Description

List of Tables

According to a new report published by Allied Market Research, titled, "API Intermediate Market," The api intermediate market was valued at $139.4 billion in 2022, and is estimated to reach $285 billion by 2032, growing at a CAGR of 7.4% from 2023 to 2032.

Active pharmaceutical ingredients (APIs) are substances or combination of substances used to manufacture a drug product. The raw material used in formulation of active pharmaceutical ingredients is known as API intermediates. API intermediates are material produced in the process of manufacturing of API. There are two types of API intermediates, which includes chemical intermediates and bulk drug intermediates. A bulk drug intermediate refers to a chemical substance or compound that is produced during the manufacturing process of a pharmaceutical drug. A chemical intermediate, on the other hand, is a compound or substance that is produced during the synthesis or production of various chemicals, including pharmaceuticals, agrochemicals, dyes, polymers, and other industrial products.

The growth of the API intermediates market is driven by rise in the prevalence of chronic diseases and increase in number of geriatric populations. APIs and intermediates possess application in high-quality drugs used for the treatment of diseases, such as oncology, cardiology, central nervous system (CNS) and neurology, orthopedic, pulmonology, gastroenterology, nephrology, ophthalmology, and endocrinology. APIs and intermediates can potentially create a more sustainable healthcare system by introducing more innovative products. Thus, rise in number of populations suffering from chronic diseases, such as cardiac diseases, is anticipated to fuel the demand for API intermediates and boosts the market growth. For instance, according to the British Heart Foundation, around 1,139,140 people were suffering from heart and circulatory diseases in the UK in 2022. As per the same source, around 650,681 male and 488,320 female population were suffering from heart and circulatory diseases in the UK in 2022.

Moreover, according to the American Heart Association, 244.1 million people were estimated to be living with ischemic heart disease (IHD) in 2020. As per the same source, IHD was more prevalent in males than in females, 141.0 and 103.1 million people, respectively.

In addition, the American Cancer Society reported that, around 1,918,030 new cases of cancer detected in the U.S. in 2022. Moreover, World Cancer Research Fund International, (WCRFI), reported that around 18.1 million new cancer cases were detected in 2020 globally. Furthermore, rise in number of populations suffering from pulmonary and gastrointestinal disorders is expected to increase the demand for API intermediates and fuels the growth of the market. The global initiative for chronic obstructive lung disease (GOLD), in 2022, reported that 200 million people had chronic obstructive pulmonary disease (COPD), of which about 3.2 million die each year, making it the third-leading cause of death globally. In addition, as per the same source, asthma is one of the most common non-communicable diseases, globally affecting 262 million people in 2022.

High presence of companies who manufacture API intermediates is anticipated to boost the growth of the market. For instance, Shubham Specialty Products, Akums Drugs & Pharmaceuticals Ltd., Vasoya Industrial Pvt. Lmt., Corey Organics, Icon Pharma Chem, and SLN Pharmachem are some of the key market players who manufacture API intermediates.

However, the high cost associated with the acquisition of biopharmaceutical drugs is a major factor hampering the growth of global API intermediates market. Also, the high cAPItal investment required to produce API intermediates is expected to restrain the market growth.

On the contrary, rise in initiative taken by government of different countries such as India, China, Japan, and others, for development of healthcare infrastructure and increase in expenditure for development of API intermediates manufacturing units are anticipated to offer remunerative opportunities for the expansion of the market during the forecast period.

The global API intermediates market is segmented into type, application, end user, and region. By type, the market is divided into bulk drug intermediates and chemical intermediates. On the basis of application, the market is divided into analgesics, anti-infective drugs, antidiabetic drugs, cardiovascular drugs, anticancer drugs and others. By end user, the market is segmented into biotech & pharmaceutical companies, CMO and research laboratories. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Some of the major companies that operate in the global API intermediates market include: Anyang General Chemical Co., Ltd., Sandoo Pharmaceuticals, Evonik Industries AG, Shree Ganesh Remedies Limited, Pfizer, Cambrex Corporation, Zeal & Innovation in Medicine, cation pharma, Hikal Ltd., and Espee.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the API intermediate market analysis from 2022 to 2032 to identify the prevailing API intermediate market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the API intermediate market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global API intermediate market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

Bulk Drug Intermediates
Chemical Intermediates

By Application

Analgesics
Anti-Infective Drugs
Antidiabetic Drugs
Cardiovascular Drugs
Anticancer Drugs
Others

By End User

Biotech and Pharmaceutical Companies
CMO
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Anyang General Chemical Co., Ltd.
Cambrex Corporation
Cation Pharma
Espee
Evonik Industries AG.
Hikal Ltd
Pfizer Inc.
Sandoo Pharmaceuticals
Shree Ganesh Remedies Limited
Zeal & Innovation in Medicine

Product Code: A02308

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Low bargaining power of suppliers
- 3.3.2. Low threat of new entrants
- 3.3.3. Low threat of substitutes
- 3.3.4. Low intensity of rivalry
- 3.3.5. Low bargaining power of buyers
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Rise in prevalence of chronic disease
  - 3.4.1.2. High presence of market players
  - 3.4.1.3. Surge in number of geriatric populations

3.4.2. Restraints
- 3.4.2.1. Stringent government rules

3.4.3. Opportunities
- 3.4.3.1. Rapid growth of biopharmaceutical industry
- 3.4.3.2. Increase in adoptions of key strategies by market players.

3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: API INTERMEDIATE MARKET, BY TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Bulk Drug Intermediates
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Chemical Intermediates
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country

CHAPTER 5: API INTERMEDIATE MARKET, BY APPLICATION

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Analgesics
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Anti-Infective Drugs
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Antidiabetic Drugs
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
5.5. Cardiovascular Drugs
- 5.5.1. Key market trends, growth factors and opportunities
- 5.5.2. Market size and forecast, by region
- 5.5.3. Market share analysis by country
5.6. Anticancer Drugs
- 5.6.1. Key market trends, growth factors and opportunities
- 5.6.2. Market size and forecast, by region
- 5.6.3. Market share analysis by country
5.7. Others
- 5.7.1. Key market trends, growth factors and opportunities
- 5.7.2. Market size and forecast, by region
- 5.7.3. Market share analysis by country

CHAPTER 6: API INTERMEDIATE MARKET, BY END USER

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Biotech and Pharmaceutical Companies
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. CMO
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Others
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country

CHAPTER 7: API INTERMEDIATE MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key trends and opportunities
- 7.2.2. Market size and forecast, by Type
- 7.2.3. Market size and forecast, by Application
- 7.2.4. Market size and forecast, by End User
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Key market trends, growth factors and opportunities
  - 7.2.5.1.2. Market size and forecast, by Type
  - 7.2.5.1.3. Market size and forecast, by Application
  - 7.2.5.1.4. Market size and forecast, by End User
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Key market trends, growth factors and opportunities
  - 7.2.5.2.2. Market size and forecast, by Type
  - 7.2.5.2.3. Market size and forecast, by Application
  - 7.2.5.2.4. Market size and forecast, by End User
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Key market trends, growth factors and opportunities
  - 7.2.5.3.2. Market size and forecast, by Type
  - 7.2.5.3.3. Market size and forecast, by Application
  - 7.2.5.3.4. Market size and forecast, by End User
7.3. Europe
- 7.3.1. Key trends and opportunities
- 7.3.2. Market size and forecast, by Type
- 7.3.3. Market size and forecast, by Application
- 7.3.4. Market size and forecast, by End User
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Key market trends, growth factors and opportunities
  - 7.3.5.1.2. Market size and forecast, by Type
  - 7.3.5.1.3. Market size and forecast, by Application
  - 7.3.5.1.4. Market size and forecast, by End User
  - 7.3.5.2. France
  - 7.3.5.2.1. Key market trends, growth factors and opportunities
  - 7.3.5.2.2. Market size and forecast, by Type
  - 7.3.5.2.3. Market size and forecast, by Application
  - 7.3.5.2.4. Market size and forecast, by End User
  - 7.3.5.3. UK
  - 7.3.5.3.1. Key market trends, growth factors and opportunities
  - 7.3.5.3.2. Market size and forecast, by Type
  - 7.3.5.3.3. Market size and forecast, by Application
  - 7.3.5.3.4. Market size and forecast, by End User
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Key market trends, growth factors and opportunities
  - 7.3.5.4.2. Market size and forecast, by Type
  - 7.3.5.4.3. Market size and forecast, by Application
  - 7.3.5.4.4. Market size and forecast, by End User
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Key market trends, growth factors and opportunities
  - 7.3.5.5.2. Market size and forecast, by Type
  - 7.3.5.5.3. Market size and forecast, by Application
  - 7.3.5.5.4. Market size and forecast, by End User
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Key market trends, growth factors and opportunities
  - 7.3.5.6.2. Market size and forecast, by Type
  - 7.3.5.6.3. Market size and forecast, by Application
  - 7.3.5.6.4. Market size and forecast, by End User
7.4. Asia-Pacific
- 7.4.1. Key trends and opportunities
- 7.4.2. Market size and forecast, by Type
- 7.4.3. Market size and forecast, by Application
- 7.4.4. Market size and forecast, by End User
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Key market trends, growth factors and opportunities
  - 7.4.5.1.2. Market size and forecast, by Type
  - 7.4.5.1.3. Market size and forecast, by Application
  - 7.4.5.1.4. Market size and forecast, by End User
  - 7.4.5.2. China
  - 7.4.5.2.1. Key market trends, growth factors and opportunities
  - 7.4.5.2.2. Market size and forecast, by Type
  - 7.4.5.2.3. Market size and forecast, by Application
  - 7.4.5.2.4. Market size and forecast, by End User
  - 7.4.5.3. India
  - 7.4.5.3.1. Key market trends, growth factors and opportunities
  - 7.4.5.3.2. Market size and forecast, by Type
  - 7.4.5.3.3. Market size and forecast, by Application
  - 7.4.5.3.4. Market size and forecast, by End User
  - 7.4.5.4. Australia
  - 7.4.5.4.1. Key market trends, growth factors and opportunities
  - 7.4.5.4.2. Market size and forecast, by Type
  - 7.4.5.4.3. Market size and forecast, by Application
  - 7.4.5.4.4. Market size and forecast, by End User
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Key market trends, growth factors and opportunities
  - 7.4.5.5.2. Market size and forecast, by Type
  - 7.4.5.5.3. Market size and forecast, by Application
  - 7.4.5.5.4. Market size and forecast, by End User
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Key market trends, growth factors and opportunities
  - 7.4.5.6.2. Market size and forecast, by Type
  - 7.4.5.6.3. Market size and forecast, by Application
  - 7.4.5.6.4. Market size and forecast, by End User
7.5. LAMEA
- 7.5.1. Key trends and opportunities
- 7.5.2. Market size and forecast, by Type
- 7.5.3. Market size and forecast, by Application
- 7.5.4. Market size and forecast, by End User
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Key market trends, growth factors and opportunities
  - 7.5.5.1.2. Market size and forecast, by Type
  - 7.5.5.1.3. Market size and forecast, by Application
  - 7.5.5.1.4. Market size and forecast, by End User
  - 7.5.5.2. Saudi Arabia
  - 7.5.5.2.1. Key market trends, growth factors and opportunities
  - 7.5.5.2.2. Market size and forecast, by Type
  - 7.5.5.2.3. Market size and forecast, by Application
  - 7.5.5.2.4. Market size and forecast, by End User
  - 7.5.5.3. South Africa
  - 7.5.5.3.1. Key market trends, growth factors and opportunities
  - 7.5.5.3.2. Market size and forecast, by Type
  - 7.5.5.3.3. Market size and forecast, by Application
  - 7.5.5.3.4. Market size and forecast, by End User
  - 7.5.5.4. Rest of LAMEA
  - 7.5.5.4.1. Key market trends, growth factors and opportunities
  - 7.5.5.4.2. Market size and forecast, by Type
  - 7.5.5.4.3. Market size and forecast, by Application
  - 7.5.5.4.4. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

9.1. Anyang General Chemical Co., Ltd.
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
9.2. Sandoo Pharmaceuticals
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
9.3. Evonik Industries AG.
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
9.4. Shree Ganesh Remedies Limited
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
9.5. Cambrex Corporation
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Key strategic moves and developments
9.6. Zeal & Innovation in Medicine
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
9.7. Cation Pharma
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
9.8. Espee
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
9.9. Hikal Ltd
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
9.10. Pfizer Inc.
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance